We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
- Authors
von Pawel, J; Schiller, J H; Shepherd, F A; Fields, S Z; Kleisbauer, J P; Chrysson, N G; Stewart, D J; Clark, P I; Palmer, M C; Depierre, A; Carmichael, J; Krebs, J B; Ross, G; Lane, S R; Gralla, R
- Abstract
Topotecan and cyclophosphamide, doxorubicin, and vincristine (CAV) were evaluated in a randomized, multicenter study of patients with small-cell lung cancer (SCLC) who had relapsed at least 60 days after completion of first-line therapy.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Vol 17, Issue 2, p658
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1999.17.2.658